An observational study in NSCLC Stage IIIB, NSCLC Stage IIIC, sponsored by West China Hospital. Not yet recruiting. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-27.
Sponsored by West China Hospital · Observational
This is an observational study evaluating the clinical characteristics, treatment patterns, and clinical outcomes in Stage III (cTNM-IIIB/IIIC) Non-Small Cell Lung Cancer.Patients meeting inclusion and exclusion criteria were enrolled, with treatment modalities and clinical outcomes of stage III non-small cell lung cancer (NSCLC) patients from multiple tertiary hospitals in real-world settings since August 2020 being collected and analyzed.
Key Inclusion Population： Stage IIIB/IIIC NSCLC patients confirmed by histological or cytological examination based on the 8th edition of the AJCC staging system.Patients were negative for EGFR-sensitive mutations or ALK/ROS1 fusion alterations.
No prior chemotherapy, radiotherapy, surgical intervention, or immunotherapy had been administered.ECOG PS scores of the enrolled patients ranged from 0 to 2.
Neoadjuvant/Induction Therapy Regimen:
Tislelizumab combined with platinum-based doublet chemotherapy was administered for at Least Two Cycles , followed by surgical resection or other therapeutic interventions (e.g., radiotherapy/chemotherapy). Real-world clinical outcomes were collected and analyzed based on patients' subsequent treatment pathways.Clinical Stage IIIB-IIIC Non-Small Cell Lung Cancer (AJCC 8th Edition Staging); ECOG PS Score 0-2
Retrospective data collection was conducted for cases prior to site initiation, while prospective collection was implemented for post-initiation cases.
Collected parameters include:
6,488 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,630 are open to participants now.
This study's planned enrollment of 200 is above the median of 161 across 948 observational studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →West China Hospital is the lead sponsor of 483 studies on the registry; 240 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Stage IIIB/IIIC NSCLC patients confirmed by histological or cytological examination based on the 8th edition of the AJCC staging system.
Stage IIIB/IIIC NSCLC patients confirmed by histological or cytological examination based on the 8th edition of the AJCC staging system.
Patients were negative for EGFR-sensitive mutations or ALK/ROS1 fusion alterations.
No prior chemotherapy, radiotherapy, surgical intervention, or immunotherapy had been administered.
ECOG PS scores of the enrolled patients ranged from 0 to 2.
Exclusion Criteria:
Patients with other previous malignancies did not require additional treatment. Patients with incomplete key baseline and treatment information:including clinical stage, pathological type, neoadjuvant treatment, pathological response, imaging response after neoadjuvant.
Patients included in anti-tumor drug intervention or unblinded clinical trials, in which the treatment being administered is unknown.
Prior surgery, radiotherapy or systemic therapy for NSCLC, including radiofrequency ablation, etc.
Tislelizumab Combined with Chemotherapy as Induction Therapy
major pathological response
viable tumor cell less than 10%
Time frame: ;usually 1 week after surgery
R0 resection rate
margin negative resection
Time frame: ,usually 1 week after surgery
Down-staging rate
clinical and pathological downstaging
Time frame: usually 1 week after surgery
Impact of Neoadjuvant Therapy on Surgical Outcomes
Surgical Rate
Time frame: usually 1 week after surgery
The outcome of survival
patterns and Outcomes of Postoperative Disease Recurrence/Progression
Time frame: usually 12 month after Induction Therapy
12month event-free survival rate
the time from randomization to any progression of disease precluding surgery, progresson or recurrence of disease after surgery, progression of disease in the absence of surgery, or death from any cases;
Time frame: rom date of diagnosis until the date of first documented progression, the rate of recurrence or date of death from any cause, whichever came first, assessed up to 12 months
OS
From diagnosis to the death;
Time frame: from date of diagnosis until the date of death from any cause, whichever came first, assessed up to 60 months
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung→
West China Hospital